BetterLife Pharma Inc. announced it has completed its 4-week oral BETR-001 GLP toxicology study in animals. The study demonstrated that BETR-001's repeated dosing for 4 weeks is very well-tolerated. The study findings support a broad therapeutic window for the use of BETR-001 in humans.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0872 USD | +4.62% | -6.13% | +81.88% |
05-03 | BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in funding | CI |
05-01 | BetterLife Pharma Advances IND-enabling Studies For BETR-001 | MT |
1st Jan change | Capi. | |
---|---|---|
+81.88% | 10.12M | |
+5.66% | 111B | |
+11.23% | 105B | |
-2.36% | 21.93B | |
-12.15% | 22.34B | |
-5.66% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- BETRF Stock
- News BetterLife Pharma Inc.
- BetterLife Pharma Inc. Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001